Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2009 (2009), Article ID 621780, 8 pages
http://dx.doi.org/10.1155/2009/621780
Clinical Study

Kinetics and Determining Factors of the Virologic Response to Antiretrovirals during Pregnancy

1Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO 80045, USA
2Department of Pediatrics, The Children’s Hospital, Aurora, CO 80045, USA
3Department of Obstetrics and Gynecology, University of Colorado Denver School of Medicine, Aurora, CO 80045, USA
4University of Colorado Denver School of Medicine, Aurora, CO 80045, USA
5Department of Infectious Diseases, National Jewish Hospital, Denver, CO 80206, USA

Received 23 June 2009; Accepted 15 October 2009

Academic Editor: Grace John-Stewart

Copyright © 2009 Adriana Weinberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Thorne, “Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy,” Clinical Infectious Diseases, vol. 40, no. 3, pp. 458–465, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. C. L. Townsend, M. Cortina-Borja, C. S. Peckham, A. de Ruiter, H. Lyall, and P. A. Tookey, “Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006,” AIDS, vol. 22, no. 8, pp. 973–981, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Warszawski, R. Tubiana, J. Le Chenadec et al., “Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort,” AIDS, vol. 22, no. 2, pp. 289–299, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. E. R. Cooper, M. Charurat, D. N. Burns, W. Blattner, and R. Hoff, “Trends in antiretroviral therapy and mother-infant transmission of HIV. The Women and Infants Transmission Study Group,” Journal of Acquired Immune Deficiency Syndromes, vol. 24, no. 1, pp. 45–47, 2000. View at Google Scholar · View at Scopus
  5. A. Dorenbaum, C. K. Cunningham, R. D. Gelber et al., “Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial,” Journal of the American Medical Association, vol. 288, no. 2, pp. 189–198, 2002. View at Google Scholar · View at Scopus
  6. J. P. A. Ioannidis, E. J. Abrams, A. Ammann et al., “Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000?copies/mL,” Journal of Infectious Diseases, vol. 183, no. 4, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. C. N. Hudson, “Elective caesarean section for prevention of vertical transmission of HIV-1 infection,” The Lancet, vol. 353, no. 9158, pp. 1030–1031, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Jourdain, J.-Y. Mary, S. Le Coeur et al., “Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand,” Journal of Infectious Diseases, vol. 196, no. 11, pp. 1629–1636, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. D. K. Ekouevi, A. Inwoley, B. Tonwe-Gold et al., “Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings,” AIDS Research and Human Retroviruses, vol. 23, no. 12, pp. 1469–1474, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Patel, M. Cortina-Borja, C. Thorne et al., “Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women,” Clinical Infectious Diseases, vol. 44, no. 12, pp. 1647–1656, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Manavi, A. McDonald, and A. Al-Sharqui, “Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine,” AIDS, vol. 21, no. 5, pp. 643–645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. M. Stek, M. Mirochnick, E. Capparelli et al., “Reduced lopinavir exposure during pregnancy,” AIDS, vol. 20, no. 15, pp. 1931–1939, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Ghosn, I. De Montgolfier, C. Cornélie et al., “Antiretroviral therapy with a twice-daily regimen containing 400?milligrams of indinavir and 100?milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1542–1544, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Liang, H. Wu, and R. J. Carroll, “The relationship between virologic and immunologic responses in AIDS clinical research using mixed-effects varying-coefficient models with measurement error,” Biostatistics, vol. 4, no. 2, pp. 297–312, 2003. View at Google Scholar · View at Scopus
  15. R. C. Littell, G. A. Milliken, W. W. Stroup, and R. D. Wolfinger, SAS System for Mixed Models, SAS Institute, 1996.
  16. A. Weinberg, J. Forster-Harwood, E. J. McFarland et al., “Resistance to antiretrovirals in HIV-infected pregnant women,” Journal of Clinical Virology, vol. 45, no. 1, pp. 39–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Gartland, “AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients,” Antiviral Therapy, vol. 6, no. 2, pp. 127–134, 2001. View at Google Scholar · View at Scopus
  18. R. L. Murphy, S. Brun, C. Hicks et al., “ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results,” AIDS, vol. 15, no. 1, pp. F1–F9, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Nan, N. Harris, M. Lisa et al., “Enhanced perinatal surveillance- United States, 1999–2001,” Special Surveillance Report 4, US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga, USA, 2004. View at Google Scholar
  20. S. Walmsley, B. Bernstein, M. King et al., “Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection,” The New England Journal of Medicine, vol. 346, no. 26, pp. 2039–2046, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Gingelmaier, M. Kurowski, R. Kästner et al., “Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery,” AIDS, vol. 20, no. 13, pp. 1737–1743, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. E. P. Acosta, A. Bardeguez, C. D. Zorrilla et al., “Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 2, pp. 430–436, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. J. F. J. B. Nellen, I. Schillevoort, F. W. N. M. Wit et al., “Nelfinavir plasma concentrations are low during pregnancy,” Clinical Infectious Diseases, vol. 39, no. 5, pp. 736–740, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Burger, P. Hugen, P. Reiss et al., “Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals,” AIDS, vol. 17, no. 8, pp. 1157–1165, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Durant, P. Clevenbergh, R. Garraffo et al., “Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study,” AIDS, vol. 14, no. 10, pp. 1333–1339, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Durant, P. Clevenbergh, P. Halfon et al., “Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial,” The Lancet, vol. 353, no. 9171, pp. 2195–2199, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Clevenbergh, R. Garraffo, J. Durant, and P. Dellamonica, “PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results,” AIDS, vol. 16, no. 17, pp. 2311–2315, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. C. J. L. La Porte, D. J. Back, T. Blaschke et al., “Updated guideline to perform therapeutic drug monitoring for antiretroviral agents,” Reviews in Antiviral Therapy, vol. 2006, no. 3, pp. 4–14, 2006. View at Google Scholar
  29. J. McNabb, J. W. Ross, K. Abriola, C. Turley, C. H. Nightingale, and D. P. Nicolau, “Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic,” Clinical Infectious Diseases, vol. 33, no. 5, pp. 700–705, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. A. D. Bardeguez, J. C. Lindsey, M. Shannon et al., “Adherence to antiretrovirals among US women during and after pregnancy,” Journal of Acquired Immune Deficiency Syndromes, vol. 48, no. 4, pp. 408–417, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. S. C. J. M. Vervoort, J. C. C. Borleffs, A. I. M. Hoepelman, and M. H. F. Grypdonck, “Adherence in antiretroviral therapy: a review of qualitative studies,” AIDS, vol. 21, no. 3, pp. 271–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Osterberg and T. Blaschke, “Adherence to medication,” The New England Journal of Medicine, vol. 353, no. 5, pp. 487–497, 2005. View at Publisher · View at Google Scholar · View at Scopus